What are the functions and effects of tofacitinib/Shangjie?

Tofacitinib is an oral Janus kinase (JAK) inhibitor that plays an important role in the management of modern rheumatic immune diseases. Compared with traditional chemotherapy drugs and biological agents, tofacitinib has the characteristics of a small molecule targeted drug, which can exert immunomodulatory and anti-inflammatory effects by blocking inflammatory signaling pathways, bringing more possibilities for long-term disease control.

From the perspective of its mechanism of action, the target of tofacitinib is theJAK-STAT signaling pathway. This pathway plays a key role in a variety of immune responses and inflammatory responses, especially involving leukocyte differentiation and inflammatory cytokine release. Tofacitinib inhibits the activity of JAK1, JAK3 and part of JAK2, thereby reducing the activation of multiple inflammatory factors and reducing the excessive response of the immune system. Unlike biological agents that directly target a single inflammatory factor, tofacitinib is a "multi-pathway modulator" and therefore has more advantages in controlling the breadth and depth of inflammation.

In terms of indications, tofacitinib is mainly used to treat chronic immune diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis (UC), ankylosing spondylitis, etc. For patients with rheumatoid arthritis, tofacitinib can not only effectively relieve joint pain, swelling and stiffness, but also delay joint destruction and improve quality of life. For psoriatic arthritis, it can relieve joint symptoms, improve skin lesions, and have a comprehensive regulatory effect on the whole body. In the treatment of ulcerative colitis, tofacitinib helps patients achieve clinical remission and mucosal healing by inhibiting inflammatory cell infiltration and mucosal damage.

The efficacy of tofacitinib is also reflected in the convenience of administration. As an oral small molecule drug, it avoids the inconvenience of injection or infusion of biological agents, allowing patients to use it regularly at home for a long time. Many overseas studies have shown that tofacitinib works quickly, and some patients can feel improvement in joint symptoms within a few weeks of taking the drug, which has positive significance in alleviating the pain of long-term chronic diseases. At the same time, its reversible mechanism of action also provides flexibility for dose adjustment and individualized management.

In addition, tofacitinib’s unique immunological effects also show promise in some refractory patients. For example, some patients who have had an inadequate response to methotrexate or traditional biologics may have new treatment opportunities by switching to tofacitinib. This "complementary mechanism" feature makes tofacitinib an indispensable treatment option in the field of rheumatism and immunity.

However, the use of tofacitinib also comes with certain risks. Because it reduces inflammation by suppressing immune pathways, patients may be at increased risk for infections, particularly opportunistic infections such as shingles. In addition, it is also necessary to pay attention to changes in blood lipids, liver function indicators and the risk of cardiovascular events. Therefore, the efficacy of tofacitinib is not only reflected in its "potent anti-inflammatory", but also in its "precision and controllability". Doctors will conduct risk assessment and monitoring based on individual patient differences to ensure a balance between efficacy and safety.

Reference materials:https://www.xeljanz.com/